Jubilant Pharmova vs Concord Biotech: Share Price, PE, ROE Compared

August 12, 2026
Posted by: Kunal Singla
Category: Market

Jubilant Pharmova MCap Rs 15,320 Cr, PE 38.55x, ROE 5.62%. Concord Biotech MCap Rs 14,824 Cr, PE 54.33x, ROE 12.94%, zero debt. Near-equal size!

Jubilant Pharmova vs Concord Biotech is a comparison specialty pharma investors look up when evaluating two nearly equal-sized Indian companies in different pharmaceutical niches. Jubilant Pharmova, a Noida-based company, is a specialty pharmaceutical and CDMO (contract development and manufacturing) company – it makes radiopharmaceuticals for nuclear medicine, pyridines and specialty chemicals, and provides CDMO services. Concord Biotech, a Ahmedabad-based company, manufactures fermentation-based APIs (active pharmaceutical ingredients) – primarily immunosuppressants (tacrolimus, sirolimus) and fermentation-based molecules for global pharma companies. The Jubilant Pharmova versus Concord Biotech comparison is a remarkably close size match (Rs 15,320 Cr vs Rs 14,824 Cr – less than 500 Cr difference).

This Jubilant Pharmova vs Concord Biotech article covers reach and market position, key products, latest declared results and stock valuation. All data is sourced from Groww and public company filings.

Table of Contents

Reach and Market Position

In this Jubilant Pharmova vs Concord Biotech comparison, Jubilant Pharmova provides radiopharmaceuticals to nuclear medicine centres in North America, specialty chemicals (pyridines) to global pharma, and CDMO services to pharmaceutical companies. Market capitalisation is Rs 15,320 Cr.

Click Here – Get Free Investment Predictions

Concord Biotech manufactures fermentation-derived APIs (tacrolimus, sirolimus, cyclosporine) for immunosuppression treatments and supplies to global pharmaceutical companies. Market capitalisation is Rs 14,824 Cr.

Key Products and Business Mix

For the Jubilant Pharmova vs Concord Biotech product breakdown, Jubilant Pharmova: Jubilant earns from radiopharmaceuticals, pyridine chemicals and CDMO contracts. EPS is Rs 24.95. PE is 38.55x, ROE 5.62 percent, D/E 0.51.

Concord Biotech: Concord Biotech earns from fermentation-based immunosuppressant APIs. EPS is Rs 26.08. PE is 54.33x, ROE 12.94 percent, zero debt, Div 0.53 percent.

Latest Results and Financial Data

On the Jubilant Pharmova vs Concord Biotech results front: Jubilant Pharmova has a market cap of Rs 15,320 Cr and PE of 38.55x. ROE is 5.62 percent. Jubilant and Concord are almost identical in market cap – one of the closest matched pairs in this batch.

Concord Biotech has a market cap of Rs 14,824 Cr and PE of 54.33x. ROE is 12.94 percent (significantly higher than Jubilant). Concord has zero debt.

Compare Jubilant Pharmova and Concord Biotech Fundamentals on the Univest Screener

Stock Performance and Valuation

Investors tracking the Jubilant Pharmova vs Concord Biotech comparison should verify current prices on NSE or BSE before trading. The Jubilant Pharmova vs Concord Biotech stock data below reflects the latest available figures from Groww and public company filings.

Jubilant Pharmova versus Concord Biotech: near-equal market caps (Rs 15,320 Cr vs Rs 14,824 Cr). Jubilant (PE 38.55x, ROE 5.62%) vs Concord (PE 54.33x, ROE 12.94%, zero debt). Comparing Jubilant Pharmova and Concord Biotech, Jubilant is cheaper on PE but Concord has much higher ROE and zero debt.

Jubilant Pharmova vs Concord Biotech: Quick Comparison Table

The comparison table below summarises the key metrics side by side.

Parameter	Jubilant Pharmova	Concord Biotech
Sector	Radiopharma + pyridines + CDMO specialty pharma (Jubilant group, Noida)	Fermentation APIs: tacrolimus, sirolimus, cyclosporine (Ahmedabad)
Market Cap	Rs 15,320 Cr	Rs 14,824 Cr (near-equal!)
P/E Ratio	38.55x (cheaper)	54.33x
ROE	5.62%	12.94% (more than double)
Debt to Equity	0.51	0.00 (zero debt!)
Revenue Driver	Radiopharma (N. America) + pyridines + CDMO	Immunosuppressant APIs (global pharma B2B)
Dividend Yield	0.52%	0.53%

Conclusion

The Jubilant Pharmova vs Concord Biotech comparison above covers reach, products, results and valuation. Jubilant Pharmova versus Concord Biotech covers radiopharma and specialty CDMO versus fermentation-based immunosuppressant APIs. Both have near-identical market caps. Concord has a higher ROE and zero debt. Jubilant is cheaper on PE. The Jubilant Pharmova and Concord Biotech comparison is one of the closest value-matches in this batch. Consult a SEBI-registered advisor for personalised guidance.

Download the Univest iOS App or Univest Android App to track Jubilant Pharmova and Concord Biotech live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What does Jubilant Pharmova do?

Ans. Jubilant Pharmova manufactures radiopharmaceuticals (radioactive drugs for PET scans and nuclear medicine) for North America, specialty chemicals (pyridines) for global pharma, and provides CDMO manufacturing services.

What does Concord Biotech make?

Ans. Concord Biotech manufactures APIs through fermentation – primarily immunosuppressant molecules like tacrolimus (anti-organ rejection), sirolimus and cyclosporine, sold to global pharmaceutical companies.

What is a radiopharmaceutical?

Ans. Radiopharmaceuticals are drugs containing radioactive substances used for diagnosis (PET scans, SPECT scans) and treatment (targeted radiation therapy) in nuclear medicine. Jubilant Pharmova is a leading radiopharmaceutical supplier in North America.

What is fermentation in pharma?

Ans. Fermentation uses microorganisms (bacteria, fungi) to produce complex organic molecules (APIs) that are difficult to make chemically. Concord Biotech produces immunosuppressant APIs through fermentation.

Which is larger, Jubilant Pharmova or Concord Biotech?

Ans. Jubilant Pharmova at Rs 15,320 Cr is only marginally larger than Concord Biotech at Rs 14,824 Cr – less than 500 Cr difference, making them one of the closest-matched pairs.

Do both pay dividends?

Ans. Yes. Both pay approximately 0.52-0.53 percent dividend yield.

Are these companies in Nifty 50?

Ans. Neither is in Nifty 50.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.